Fatigue in adults with spinal muscular atrophy under treatment with nusinersen.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 07 2020
06 07 2020
Historique:
received:
14
02
2020
accepted:
18
06
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
15
12
2020
Statut:
epublish
Résumé
5q-Associated spinal muscular atrophy is a hereditary neuromuscular disease leading to progressive muscle weakness in which fatigue occurs and affects quality of life. Treatment with the antisense oligonucleotide nusinersen has been shown to improve motor function. Fatigue can be measured within the Fatigue Severity Scale (FSS). FSS is a self-reported questionnaire consisting of nine items to quantify fatigue severity within the last week. Higher values indicating a higher severity. Using the FSS, fatigue was measured in 28 adult patients, subdivided into ambulatory and non-ambulatory, suffering from a genetically confirmed 5q-SMA under treatment with nusinersen in accordance with the label. Correlations were performed among FSS and motor scales, 6-minute walk test (6MWT) and Hammersmiths Functional Motor Scale Expanded (HFMSE). Evaluation was performed prior to treatment initiation and after 6 and 10 months. The mean FSS score for all 28 patients at baseline was 4.61 ± 1.44. After 6 months mean FSS score significantly reduced to 3.92 ± 1.35. After 10 months mean FSS score had not differed from baseline, 3.84 ± 1.25. A moderate negative correlation of the difference of FSS and 6MWT after 6 months compared to baseline conditions was measured. Nusinersen reduces fatigue as measured by the FSS in adult patients with 5q-SMA transiently after initiation of treatment. There was no reduction of FSS 10 months after the beginning of treatment when compared to baseline.
Identifiants
pubmed: 32632203
doi: 10.1038/s41598-020-68051-w
pii: 10.1038/s41598-020-68051-w
pmc: PMC7338415
doi:
Substances chimiques
Oligonucleotides
0
Survival of Motor Neuron 1 Protein
0
nusinersen
5Z9SP3X666
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11069Références
Lefebvre, S. et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16, 265–269. https://doi.org/10.1038/ng0797-265 (1997).
doi: 10.1038/ng0797-265
pubmed: 9207792
Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 (1995).
doi: 10.1016/0092-8674(95)90460-3
Mercuri, E., Bertini, E. & Iannaccone, S. T. Childhood spinal muscular atrophy: Controversies and challenges. Lancet Neurol. 11, 443–452. https://doi.org/10.1016/S1474-4422(12)70061-3 (2012).
doi: 10.1016/S1474-4422(12)70061-3
pubmed: 22516079
Boido, M. & Vercelli, A. Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy. Front. Neuroanat. 10, 6. https://doi.org/10.3389/fnana.2016.00006 (2016).
doi: 10.3389/fnana.2016.00006
pubmed: 26869891
pmcid: 4737916
Zerres, K. et al. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J. Neurol. Sci. 146, 67–72 (1997).
doi: 10.1016/S0022-510X(96)00284-5
Munsat, T. L. & Davies, K. E. International SMA consortium meeting. (26–28 June 1992, Bonn, Germany). Neuromuscul. Disord. 2, 423–428 (1992).
doi: 10.1016/S0960-8966(06)80015-5
D’Amico, A., Mercuri, E., Tiziano, F. D. & Bertini, E. Spinal muscular atrophy. Orphanet. J. Rare Dis. 6, 71. https://doi.org/10.1186/1750-1172-6-71 (2011).
doi: 10.1186/1750-1172-6-71
pubmed: 22047105
pmcid: 3231874
Landmark-Hoyvik, H. et al. The genetics and epigenetics of fatigue. PMR 2, 456–465. https://doi.org/10.1016/j.pmrj.2010.04.003 (2010).
doi: 10.1016/j.pmrj.2010.04.003
Davis, M. P. & Walsh, D. Mechanisms of fatigue. J. Support. Oncol. 8, 164–174 (2010).
pubmed: 20822034
Chaudhuri, A. & Behan, P. O. Fatigue in neurological disorders. Lancet 363, 978–988. https://doi.org/10.1016/S0140-6736(04)15794-2 (2004).
doi: 10.1016/S0140-6736(04)15794-2
pubmed: 15043967
Angelini, C. & Tasca, E. Fatigue in muscular dystrophies. Neuromuscul. Disord. 22(Suppl 3), S214-220. https://doi.org/10.1016/j.nmd.2012.10.010 (2012).
doi: 10.1016/j.nmd.2012.10.010
pubmed: 23182642
pmcid: 3526799
Mattsson, M., Moller, B., Lundberg, I., Gard, G. & Bostrom, C. Reliability and validity of the Fatigue Severity Scale in Swedish for patients with systemic lupus erythematosus. Scand. J. Rheumatol. 37, 269–277. https://doi.org/10.1080/03009740801914868 (2008).
doi: 10.1080/03009740801914868
pubmed: 18612927
Kleinman, L. et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual. Life Res. 9, 499–508 (2000).
doi: 10.1023/A:1008960710415
Hewlett, S., Dures, E. & Almeida, C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res. (Hoboken) 63(Suppl 11), S263-286. https://doi.org/10.1002/acr.20579 (2011).
doi: 10.1002/acr.20579
Herlofson, K. & Larsen, J. P. Measuring fatigue in patients with Parkinson’s disease—the Fatigue Severity Scale. Eur. J. Neurol. 9, 595–600 (2002).
doi: 10.1046/j.1468-1331.2002.00444.x
Wei, Y., Speechley, K. N., Zou, G. & Campbell, C. Factors associated with health-related quality of life in children with duchenne muscular dystrophy. J. Child Neurol. 31, 879–886. https://doi.org/10.1177/0883073815627879 (2016).
doi: 10.1177/0883073815627879
pubmed: 26863997
European Medicines Agency (EMA). (2017).
Rigo, F. et al. Pharmacology of a central nervous system delivered 2’-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350, 46–55. https://doi.org/10.1124/jpet.113.212407 (2014).
doi: 10.1124/jpet.113.212407
pubmed: 24784568
pmcid: 4056267
Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732. https://doi.org/10.1056/NEJMoa1702752 (2017).
doi: 10.1056/NEJMoa1702752
pubmed: 29091570
Mercuri, E. et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625–635. https://doi.org/10.1056/NEJMoa1710504 (2018).
doi: 10.1056/NEJMoa1710504
pubmed: 29443664
Montes, J. et al. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve 60, 409–414. https://doi.org/10.1002/mus.26633 (2019).
doi: 10.1002/mus.26633
pubmed: 31298747
pmcid: 6771553
Montes, J. et al. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74, 833–838. https://doi.org/10.1212/WNL.0b013e3181d3e308 (2010).
doi: 10.1212/WNL.0b013e3181d3e308
pubmed: 20211907
pmcid: 2839195
Krupp, L. B., LaRocca, N. G., Muir-Nash, J. & Steinberg, A. D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 46, 1121–1123. https://doi.org/10.1001/archneur.1989.00520460115022 (1989).
doi: 10.1001/archneur.1989.00520460115022
pubmed: 2803071
24AbilityLab, S. R. Fatigue Severity Scale. https://www.sralab.org/rehabilitation-measures/fatigue-severity-scale (2016).
Dunaway Young, S. et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve 54, 836–842. https://doi.org/10.1002/mus.25120 (2016).
doi: 10.1002/mus.25120
pubmed: 27015431
Pera, M. C. et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 17, 39. https://doi.org/10.1186/s12883-017-0790-9 (2017).
doi: 10.1186/s12883-017-0790-9
pubmed: 28231823
pmcid: 5324197
Hagenacker, T. et al. Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study. Lancet Neurol. 19, 317–325. https://doi.org/10.1016/S1474-4422(20)30037-5 (2020).
doi: 10.1016/S1474-4422(20)30037-5
pubmed: 32199097
Walter, M. C. et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA Type 3: A prospective observational study. J. Neuromuscul. Dis. 6, 453–465. https://doi.org/10.3233/JND-190416 (2019).
doi: 10.3233/JND-190416
pubmed: 31594243
pmcid: 6918909
Noto, Y. et al. Prominent fatigue in spinal muscular atrophy and spinal and bulbar muscular atrophy: Evidence of activity-dependent conduction block. Clin. Neurophysiol. 124, 1893–1898. https://doi.org/10.1016/j.clinph.2012.12.053 (2013).
doi: 10.1016/j.clinph.2012.12.053
pubmed: 23643309
Werlauff, U., Hojberg, A., Firla-Holme, R., Steffensen, B. F. & Vissing, J. Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: Evaluation of the fatigue severity scale. Qual. Life Res. 23, 1479–1488. https://doi.org/10.1007/s11136-013-0565-8 (2014).
doi: 10.1007/s11136-013-0565-8
pubmed: 24214178
Lerdal, A., Wahl, A., Rustoen, T., Hanestad, B. R. & Moum, T. Fatigue in the general population: A translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. Scand. J. Public Health 33, 123–130. https://doi.org/10.1080/14034940410028406 (2005).
doi: 10.1080/14034940410028406
pubmed: 15823973
El-Aloul, B., Speechley, K. N., Wei, Y., Wilk, P. & Campbell, C. Fatigue in young people with Duchenne muscular dystrophy. Dev. Med. Child Neurol. https://doi.org/10.1111/dmcn.14248 (2019).
doi: 10.1111/dmcn.14248
pubmed: 30980541
Flachenecker, P. et al. Fatigue in multiple sclerosis: A comparison of different rating scales and correlation to clinical parameters. Mult. Scler. 8, 523–526. https://doi.org/10.1191/1352458502ms839oa (2002).
doi: 10.1191/1352458502ms839oa
pubmed: 12474995
Valko, P. O., Bassetti, C. L., Bloch, K. E., Held, U. & Baumann, C. R. Validation of the fatigue severity scale in a Swiss cohort. Sleep 31, 1601–1607. https://doi.org/10.1093/sleep/31.11.1601 (2008).
doi: 10.1093/sleep/31.11.1601
pubmed: 19014080
pmcid: 2579971
Dunaway Young, S. et al. Perceived fatigue in spinal muscular atrophy: A pilot study. J. Neuromuscul. Dis. 6, 109–117. https://doi.org/10.3233/JND-180342 (2019).
doi: 10.3233/JND-180342
pubmed: 30562906
Belza, B. et al. A systematic review of studies using the multidimensional assessment of fatigue scale. J. Nurs. Meas. 26, 36–75. https://doi.org/10.1891/1061-3749.26.1.36 (2018).
doi: 10.1891/1061-3749.26.1.36
pubmed: 29724278
Fisk, J. D. et al. Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clin. Infect. Dis. 18(Suppl 1), S79-83. https://doi.org/10.1093/clinids/18.supplement_1.s79 (1994).
doi: 10.1093/clinids/18.supplement_1.s79
pubmed: 8148458
Bartels, B. et al. Assessment of fatigability in patients with spinal muscular atrophy: Development and content validity of a set of endurance tests. BMC Neurol. 19, 21. https://doi.org/10.1186/s12883-019-1244-3 (2019).
doi: 10.1186/s12883-019-1244-3
pubmed: 30738436
pmcid: 6368708